Myconostica raises more capital for fungal disease tests
This article was originally published in Clinica
UK diagnostic company Myconostica has secured additional series D financing from its German distributor medac Gesellschaft fuer klinische Spezialpraeparate. The investment, of which the amount was undisclosed, will be used to further develop Myconostica's pipeline of fungal infection tests. medac is a privately-held Hamburg-based company with both pharma and diagnostic interests. It is the exclusive distributor of Myconostica's products in Germany. As part of the financing, Dr Rainer Dickhardt, medac's managing director, joins the board of directors at Manchester-based Myconostica.